- Home
- USCB vs TNXP Comparison
USCB vs TNXP Comparison
Compare USCB & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USCB
- TNXP
- Stock Information
- Founded
- USCB 2002
- TNXP 2007
- Country
- USCB United States
- TNXP United States
- Employees
- USCB N/A
- TNXP N/A
- Industry
- USCB Major Banks
- TNXP Biotechnology: Pharmaceutical Preparations
- Sector
- USCB Finance
- TNXP Health Care
- Exchange
- USCB Nasdaq
- TNXP Nasdaq
- Market Cap
- USCB 316.4M
- TNXP 272.0M
- IPO Year
- USCB 2021
- TNXP N/A
- Fundamental
- Price
- USCB $17.00
- TNXP $35.48
- Analyst Decision
- USCB Buy
- TNXP Strong Buy
- Analyst Count
- USCB 3
- TNXP 2
- Target Price
- USCB $20.50
- TNXP $585.00
- AVG Volume (30 Days)
- USCB 27.3K
- TNXP 729.5K
- Earning Date
- USCB 07-24-2025
- TNXP 08-15-2025
- Dividend Yield
- USCB 2.35%
- TNXP N/A
- EPS Growth
- USCB 78.48
- TNXP N/A
- EPS
- USCB 1.39
- TNXP N/A
- Revenue
- USCB $84,457,000.00
- TNXP $10,041,000.00
- Revenue This Year
- USCB $23.28
- TNXP $11.66
- Revenue Next Year
- USCB $7.02
- TNXP $793.18
- P/E Ratio
- USCB $12.23
- TNXP N/A
- Revenue Growth
- USCB 34.16
- TNXP N/A
- 52 Week Low
- USCB $11.88
- TNXP $6.76
- 52 Week High
- USCB $21.86
- TNXP $130.00
- Technical
- Relative Strength Index (RSI)
- USCB 59.44
- TNXP 52.96
- Support Level
- USCB $16.08
- TNXP $33.71
- Resistance Level
- USCB $17.80
- TNXP $38.13
- Average True Range (ATR)
- USCB 0.48
- TNXP 2.62
- MACD
- USCB 0.13
- TNXP -0.44
- Stochastic Oscillator
- USCB 64.09
- TNXP 61.01
About USCB USCB Financial Holdings Inc.
USCB Financial Holdings Inc is a community bank. Through its network of branches and its online banking platform, it offers customers a wide range of financial products and services such as Personal and Business Checking, Savings, Credit Cards, and Real Estate Loans.
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.